Molecular Insight in the Multifunctional Effects of Oridonin

Drugs in R and D

Volumn 15, Issue 3, 2015, Pages 233-244

  Owona, Brice Ayissi ^a   Schluesener, Herman J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ORIDONIN; REACTIVE OXYGEN METABOLITE; STRUCTURAL PROTEIN; TRANSCRIPTION FACTOR; ANTINEOPLASTIC AGENT; DITERPENE; KAURANE DERIVATIVE;

ALZHEIMER DISEASE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG FORMULATION; DRUG ISOLATION; DRUG STRUCTURE; HUMAN; IMMUNOMODULATION; INFLAMMATION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; RABDOSIA; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; ANIMAL; DRUG EFFECTS; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DITERPENES; DITERPENES, KAURANE; HUMANS; IMMUNOMODULATION; NEOPLASMS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84941190738     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.1007/s40268-015-0102-z     Document Type: Review

References (111)

1. Kuo LM, Kuo CY, Lin CY, Hung MF, Shen JJ, Hwang TL. Intracellular glutathione depletion by oridonin leads to apoptosis in hepatic stellate cells. Molecules. 2014;19(3):3327–44.
2. Kadota S, Basnet P, Ishii E, Tamura T, Namba T. Antibacterial activity of trichorabdal A from Rabdosia trichocarpa against Helicobacter pylori. Zentralblatt fur Bakteriologie: Int J Med Microbiol. 1997;286(1):63–7.
3. Liu Y, Liu YZ, Zhang RX, Wang X, Meng ZJ, Huang J, Wu K, Luo JY, Zuo GW, Chen L, et al. Oridonin inhibits the proliferation of human osteosarcoma cells by suppressing Wnt/beta-catenin signaling. Int J Oncol. 2014;45(2):795–803.
4. Xu S, Li D, Pei L, Yao H, Wang C, Cai H, Yao H, Wu X, Xu J. Design, synthesis and antimycobacterial activity evaluation of natural oridonin derivatives. Bioorg Med Chem Lett. 2014;24(13):2811–4.
5. Liu JJ, Huang RW, Lin DJ, Peng J, Wu XY, Pan XL, Li MQ, Lin Q. Anti-proliferative effects of oridonin on SPC-A-1 cells and its mechanism of action. J Int Med Res. 2004;32(6):617–25.
6. Dal Piaz F, Cotugno R, Lepore L, Vassallo A, Malafronte N, Lauro G, Bifulco G, Belisario MA, De Tommasi N. Chemical proteomics reveals HSP70 1A as a target for the anticancer diterpene oridonin in Jurkat cells. J Proteomics. 2013;82:14–26.
7. Tan W, Lu J, Huang M, Li Y, Chen M, Wu G, Gong J, Zhong Z, Xu Z, Dang Y, et al. Anti-cancer natural products isolated from chinese medicinal herbs. Chin Med. 2011;6(1):27.
8. Duan HQ, Li MY, Gao L, Zhang JF, Wang W, Li Y, Ma YG, Wang CB. Mechanism concerning antitumor effect of oridonin on multiple myeloma cell line U266. Zhongguo shi yan xue ye xue za zhi/Zhongguo bing li sheng li xue hui = J Exp Hematol/Chin Assoc Pathophysiol. 2014;22(2):364–9.
9. Zhang ZY, Daniels R, Schluesener HJ. Oridonin ameliorates neuropathological changes and behavioural deficits in a mouse model of cerebral amyloidosis. J Cell Mol Med. 2013;17(12):1566–76.
10. Huang J, Wu L, Tashiro S, Onodera S, Ikejima T. Fibroblast growth factor-2 suppresses oridonin-induced L929 apoptosis through extracellular signal-regulated kinase-dependent and phosphatidylinositol 3-kinase-independent pathway. J Pharmacol Sci. 2006;102(3):305–13.
11. Bu HQ, Liu DL, Wei WT, Chen L, Huang H, Li Y, Cui JH. Oridonin induces apoptosis in SW1990 pancreatic cancer cells via p53- and caspase-dependent induction of p38 MAPK. Oncol Rep. 2014;31(2):975–82.
12. Zhang CL, Wu LJ, Tashiro S, Onodera S, Ikejima T. Oridonin induces a caspase-independent but mitochondria- and MAPK-dependent cell death in the murine fibrosarcoma cell line L929. Biol Pharm Bull. 2004;27(10):1527–31.
13. Liu Y, Liu JH, Chai K, Tashiro S, Onodera S, Ikejima T. Inhibition of c-Met promoted apoptosis, autophagy and loss of the mitochondrial transmembrane potential in oridonin-induced A549 lung cancer cells. J Pharm Pharmacol. 2013;65(11):1622–42.
14. Harris ES, Cao S, Schoville SD, Dong C, Wang W, Jian Z, Zhao Z, Eisenberg DM, Clardy J. Selection for high oridonin yield in the Chinese medicinal plant Isodon (Lamiaceae) using a combined phylogenetics and population genetics approach. PLoS One. 2012;7(11):e50753.
15. Dong CM, Su XH, Wang L, Wang WL. Effect of N, P, K on yield and quality of Rabdosia rubescens. Zhong yao cai = Zhongyaocai = J Chin Med Mater. 2008;31(6):808–811.
16. Du Y, Liu P, Shi X, Jin Y, Wang Q, Zhang X, Sheng X, Zhang L. A novel analysis method for diterpenoids in rat plasma by liquid chromatography-electrospray ionization mass spectrometry. Anal Biochem. 2010;407(1):111–9.
17. Lu Y, Sun C, Liu R, Pan Y. Effective two-dimensional counter-current chromatographic method for simultaneous isolation and purification of oridonin and ponicidin from the crude extract of Rabdosia rubescens. J Chromatogr A. 2007;1146(1):125–30.
18. Hu AP, Du JM, Li JY, Liu JW. Oridonin promotes CD4+/CD25+ Treg differentiation, modulates Th1/Th2 balance and induces HO-1 in rat splenic lymphocytes. Inflamm Res. 2008;57(4):163–70.
19. Cui Q, Tashiro S, Onodera S, Minami M, Ikejima T. Oridonin induced autophagy in human cervical carcinoma HeLa cells through Ras, JNK, and P38 regulation. J Pharmacol Sci. 2007;105(4):317–25.
20. Cui Q, Yu JH, Wu JN, Tashiro S, Onodera S, Minami M, Ikejima T. P53-mediated cell cycle arrest and apoptosis through a caspase-3- independent, but caspase-9-dependent pathway in oridonin-treated MCF-7 human breast cancer cells. Acta Pharmacol Sin. 2007;28(7):1057–66.
21. Feng FF, Zhang DR, Tian KL, Lou HY, Qi XL, Wang YC, Duan CX, Jia LJ, Wang FH, Liu Y, et al. Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by oridonin nanosuspension. Drug Deliv. 2011;18(4):265–71.
22. Huang HL, Weng HY, Wang LQ, Yu CH, Huang QJ, Zhao PP, Wen JZ, Zhou H, Qu LH. Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis. Mol Cancer Ther. 2012;11(5):1155–65.
23. Huang J, Wu L, Tashiro S, Onodera S, Ikejima T. A comparison of the signal pathways between the TNF alpha- and oridonin-induced murine L929 fibrosarcoma cell death. Acta Med Okayama. 2005;59(6):261–70.
24. Ikezoe T, Yang Y, Bandobashi K, Saito T, Takemoto S, Machida H, Togitani K, Koeffler HP, Taguchi H. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol Cancer Ther. 2005;4(4):578–86.
25. Jin H, Tan X, Liu X, Ding Y. Downregulation of AP-1 gene expression is an initial event in the oridonin-mediated inhibition of colorectal cancer: studies in vitro and in vivo. J Gastroenterol Hepatol. 2011;26(4):706–15.
26. Jin S, Shen JN, Wang J, Huang G, Zhou JG. Oridonin induced apoptosis through Akt and MAPKs signaling pathways in human osteosarcoma cells. Cancer Biol Ther. 2007;6(2):261–8.
27. Li D, Wu LJ, Tashiro S, Onodera S, Ikejima T. Oridonin induces human epidermoid carcinoma A431 cell apoptosis through tyrosine kinase and mitochondrial pathway. J Asian Nat Prod Res. 2008;10(1–2):77–87.
28. Liu JJ, Huang RW, Lin DJ, Wu XY, Peng J, Pan XL, Lin Q, Hou M, Zhang MH, Chen F. Antiproliferation effects of oridonin on HPB-ALL cells and its mechanisms of action. Am J Hematol. 2006;81(2):86–94.
29. Wang H, Ye Y, Pan SY, Zhu GY, Li YW, Fong DW, Yu ZL. Proteomic identification of proteins involved in the anticancer activities of oridonin in HepG2 cells. Phytomedicine. 2011;18(2–3):163–9.
30. Zeng R, Chen Y, Zhao S, Cui GH. Autophagy counteracts apoptosis in human multiple myeloma cells exposed to oridonin in vitro via regulating intracellular ROS and SIRT1. Acta Pharmacol Sin. 2012;33(1):91–100.
31. Zhang CL, Wu LJ, Tashiro S, Onodera S, Ikejima T. Oridonin induces apoptosis of HeLa cells via altering expression of Bcl-2/Bax and activating caspase-3/ICAD pathway. Acta Pharmacol Sin. 2004;25(5):691–8.
32. Wang K, Zhang ZQ. Determination of oridonin and rosemarinic acid in Rabdosia rubescens by HPLC. Zhong yao cai = Zhongyaocai = J Chin Med Mater. 2007;30(11):1396–1398.
33. Cai DT, Jin H, Xiong QX, Liu WG, Gao ZG, Gu GX, Qiu YH. ER stress and ASK1-JNK activation contribute to oridonin-induced apoptosis and growth inhibition in cultured human hepatoblastoma HuH-6 cells. Mol Cell Biochem. 2013;379(1–2):161–9.
34. Chen S, Gao J, Halicka HD, Huang X, Traganos F, Darzynkiewicz Z. The cytostatic and cytotoxic effects of oridonin (Rubescenin), a diterpenoid from Rabdosia rubescens, on tumor cells of different lineage. Int J Oncol. 2005;26(3):579–88.
35. Cheng Y, Qiu F, Ye YC, Tashiro S, Onodera S, Ikejima T. Oridonin induces G2/M arrest and apoptosis via activating ERK-p53 apoptotic pathway and inhibiting PTK-Ras-Raf-JNK survival pathway in murine fibrosarcoma L929 cells. Arch Biochem Biophys. 2009;490(1):70–5.
36. Cui Q, Tashiro S, Onodera S, Minami M, Ikejima T. Autophagy preceded apoptosis in oridonin-treated human breast cancer MCF-7 cells. Biol Pharm Bull. 2007;30(5):859–64.
37. Du Y, Villeneuve NF, Wang XJ, Sun Z, Chen W, Li J, Lou H, Wong PK, Zhang DD. Oridonin confers protection against arsenic-induced toxicity through activation of the Nrf2-mediated defensive response. Environ Health Perspect. 2008;116(9):1154–61.
38. Gao FH, Hu XH, Li W, Liu H, Zhang YJ, Guo ZY, Xu MH, Wang ST, Jiang B, Liu F, et al. Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc. BMC Cancer. 2010;10:610.
39. Hsieh TC, Wijeratne EK, Liang JY, Gunatilaka AL, Wu JM. Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens. Biochem Biophys Res Commun. 2005;337(1):224–31.
40. Liu YQ, You S, Tashiro S, Onodera S, Ikejima T. Activation of phosphoinositide 3-kinase, protein kinase C, and extracellular signal-regulated kinase is required for oridonin-enhanced phagocytosis of apoptotic bodies in human macrophage-like U937 cells. J Pharmacol Sci. 2005;98(4):361–71.
41. Liu YQ, You S, Tashiro S, Onodera S, Ikejima T. Roles of Ras and extracellular signal-regulated kinase-dependent IkappaBalpha degradation in oridonin-enhanced phagocytosis of apoptotic cells by human macrophage-like U937 cells. Int Immunopharmacol. 2006;6(2):260–8.
42. Wang H, Ye Y, Chui JH, Zhu GY, Li YW, Fong DW, Yu ZL. Oridonin induces G2/M cell cycle arrest and apoptosis through MAPK and p53 signaling pathways in HepG2 cells. Oncol Rep. 2010;24(3):647–51.
43. Zhang CL, Wu LJ, Zuo HJ, Tashiro S, Onodera S, Ikejima T. Cytochrome c release from oridonin-treated apoptotic A375-S2 cells is dependent on p53 and extracellular signal-regulated kinase activation. J Pharmacol Sci. 2004;96(2):155–63.
44. Liu YQ, You S, Zhang CL, Tashiro S, Onodera S, Ikejima T. Oridonin enhances phagocytosis of UV-irradiated apoptotic U937 cells. Biol Pharm Bull. 2005;28(3):461–7.
45. Xu Y, Xue Y, Wang Y, Feng D, Lin S, Xu L. Multiple-modulation effects of Oridonin on the production of proinflammatory cytokines and neurotrophic factors in LPS-activated microglia. Int Immunopharmacol. 2009;9(3):360–5.
46. Gao FH, Liu F, Wei W, Liu LB, Xu MH, Guo ZY, Li W, Jiang B, Wu YL. Oridonin induces apoptosis and senescence by increasing hydrogen peroxide and glutathione depletion in colorectal cancer cells. Int J Mol Med. 2012;29(4):649–55.
47. Huang J, Wu L, Tashiro S, Onodera S, Ikejima T. Reactive oxygen species mediate oridonin-induced HepG2 apoptosis through p53, MAPK, and mitochondrial signaling pathways. J Pharmacol Sci. 2008;107(4):370–9.
48. Wu JN, Huang J, Yang J, Tashiro S, Onodera S, Ikejima T. Caspase inhibition augmented oridonin-induced cell death in murine fibrosarcoma l929 by enhancing reactive oxygen species generation. J Pharmacol Sci. 2008;108(1):32–9.
49. Yu Y, Fan SM, Song JK, Tashiro S, Onodera S, Ikejima T. Hydroxyl radical (.OH) played a pivotal role in oridonin-induced apoptosis and autophagy in human epidermoid carcinoma A431 cells. Biol Pharm Bull. 2012;35(12):2148–59.
50. Zang L, He H, Xu Q, Yu Y, Zheng N, Liu W, Hayashi T, Tashiro S, Onodera S, Ikejima T. Reactive oxygen species H2O2 and *OH, but not O2*(-) promote oridonin-induced phagocytosis of apoptotic cells by human histocytic lymphoma U937 cells. Int Immunopharmacol. 2013;15(2):414–23.
51. Zang L, He H, Ye Y, Liu W, Fan S, Tashiro S, Onodera S, Ikejima T. Nitric oxide augments oridonin-induced efferocytosis by human histocytic lymphoma U937 cells via autophagy and the NF-kappaB-COX-2-IL-1beta pathway. Free Radical Res. 2012;46(10):1207–19.
52. Guo Y, Shan Q, Gong Y, Lin J, Yang X, Zhou R. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway. Cancer Biol Ther. 2012;13(13):1244–54.
53. Li J, Yang L, Wu H. Oridonin induced the apoptosis of PC-3 cells and its mechanism. Zhong nan da xue xue bao Yi xue ban = J Cent S Univ Med Sci. 2011;36(8):754–759.
54. Liu JJ, Huang RW, Lin DJ, Wu XY, Peng J, Pan XL, Song YQ, Lin Q, Hou M, Wang DN, et al. Oridonin-induced apoptosis in leukemia K562 cells and its mechanism. Neoplasma. 2005;52(3):225–30.
55. Liu J, Yang F, Zhang Y, Li J. Studies on the cell-immunosuppressive mechanism of Oridonin from Isodon serra. Int Immunopharmacol. 2007;7(7):945–54.
56. Liu Y, Shi QF, Qi M, Tashiro S, Onodera S, Ikejima T. Interruption of hepatocyte growth factor signaling augmented oridonin-induced death in human non-small cell lung cancer A549 cells via c-met-nuclear factor-kappaB-cyclooxygenase-2 and c-Met-Bcl-2-caspase-3 pathways. Biol Pharm Bull. 2012;35(7):1150–8.
57. Wang S, Zhong Z, Wan J, Tan W, Wu G, Chen M, Wang Y. Oridonin induces apoptosis, inhibits migration and invasion on highly-metastatic human breast cancer cells. Am J Chin Med. 2013;41(1):177–96.
58. Bu HQ, Luo J, Chen H, Zhang JH, Li HH, Guo HC, Wang ZH, Lin SZ. Oridonin enhances antitumor activity of gemcitabine in pancreatic cancer through MAPK-p38 signaling pathway. Int J Oncol. 2012;41(3):949–58.
59. Chen G, Wang K, Yang BY, Tang B, Chen JX, Hua ZC. Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular carcinoma cells. Int J Oncol. 2012;40(1):139–47.
60. Chen S, Cooper M, Jones M, Madhuri TK, Wade J, Bachelor A, Butler-Manuel S. Combined activity of oridonin and wogonin in advanced-stage ovarian cancer cells: sensitivity of ovarian cancer cells to phyto-active chemicals. Cell Biol Toxicol. 2011;27(2):133–47.
61. Gao ZG, Ye QX, Zhang TM. Synergistic effect of oridonin and cisplatin on cytotoxicity and DNA cross-link against mouse sarcoma S180 cells in culture. Zhongguo yao li xue bao =Acta Pharmacol Sin. 1993;14(6):561–4.
62. Ding C, Zhang Y, Chen H, Yang Z, Wild C, Chu L, Liu H, Shen Q, Zhou J. Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility. J Med Chem. 2013;56(12):5048–58.
63. Xu J, Zhao J, Wang J, Feng N, Tan R, Liu Y. Study on stability of oridonin solution. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi =China J Chin Mater Med. 2009;34(1):47–9.
64. Shen J, Zhang D, Zhao Z, Jia L, Zheng D, Liu G, Hao L, Zhang Q, Tian X, Li C, et al. Synthesis, characterization, in vitro and in vivo evaluation of PEGylated oridonin conjugates. Int J Pharm. 2013;456(1):80–6.
65. Qi X, Zhang D, Xu X, Feng F, Ren G, Chu Q, Zhang Q, Tian K. Oridonin nanosuspension was more effective than free oridonin on G2/M cell cycle arrest and apoptosis in the human pancreatic cancer PANC-1 cell line. Int J Nanomed. 2012;7:1793–804.
66. Xue B, Wang Y, Tang X, Xie P, Wang Y, Luo F, Wu C, Qian Z. Biodegradable self-assembled MPEG-PCL micelles for hydrophobic oridonin delivery in vitro. J Biomed Nanotechnol. 2012;8(1):80–9.
67. Zhang P, Liu Y, Feng N, Xu J. Preparation and evaluation of self-microemulsifying drug delivery system of oridonin. Int J Pharm. 2008;355(1–2):269–76.
68. Zheng D, Duan C, Zhang D, Jia L, Liu G, Liu Y, Wang F, Li C, Guo H, Zhang Q. Galactosylated chitosan nanoparticles for hepatocyte-targeted delivery of oridonin. Int J Pharm. 2012;436(1–2):379–86.
69. Ding C, Zhang Y, Chen H, Wild C, Wang T, White MA, Shen Q, Zhou J. Overcoming synthetic challenges of oridonin A-ring structural diversification: regio- and stereoselective installation of azides and 1,2,3-triazoles at the C-1, C-2, or C-3 position. Org Lett. 2013;15(14):3718–21.
70. Ding C, Zhang Y, Chen H, Yang Z, Wild C, Ye N, Ester CD, Xiong A, White MA, Shen Q, et al. Oridonin ring A-based diverse constructions of enone functionality: identification of novel dienone analogues effective for highly aggressive breast cancer by inducing apoptosis. J Med Chem. 2013;56(21):8814–25.
71. Ding L, Zhou Q, Wang L, Wang W, Zhang S, Liu B. Comparison of cytotoxicity and DNA damage potential induced by ent-kaurene diterpenoids from Isodon plant. Nat Prod Res. 2011;25(15):1402–11.
72. Cheng Y, Qiu F, Ikejima T. Molecular mechanisms of oridonin-induced apoptosis and autophagy in murine fibrosarcoma L929 cells. Autophagy. 2009;5(3):430–1.
73. Hu HZ, Yang YB, Xu XD, Shen HW, Shu YM, Ren Z, Li XM, Shen HM, Zeng HT. Oridonin induces apoptosis via PI3K/Akt pathway in cervical carcinoma HeLa cell line. Acta Pharmacol Sin. 2007;28(11):1819–26.
74. Liu YQ, Mu ZQ, You S, Tashiro S, Onodera S, Ikejima T. Fas/FasL signaling allows extracelluar-signal regulated kinase to regulate cytochrome c release in oridonin-induced apoptotic U937 cells. Biol Pharm Bull. 2006;29(9):1873–9.
75. Liu YQ, You S, Tashiro S, Onodera S, Ikejima T. Oridonin induced U937 cell apoptosis through ERK pathway. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi =China J Chin Mater Med. 2005;30(23):1856–9.
76. Wang HJ, Li D, Yang FY, Tashiro S, Onodera S, Ikejima T. Oridonin induces human melanoma A375-S2 cell death partially through inhibiting insulin-like growth factor 1 receptor signaling. J Asian Nat Prod Res. 2008;10(7–8):787–98.
77. Zhang CL, Wu LJ, Tashiro S, Onodera S, Ikejima T. Oridonin induced A375-S2 cell apoptosis via bax-regulated caspase pathway activation, dependent on the cytochrome c/caspase-9 apoptosome. J Asian Nat Prod Res. 2004;6(2):127–38.
78. Chen S, Gao J, Halicka HD, Traganos F, Darzynkiewicz Z. Down-regulation of androgen-receptor and PSA by phytochemicals. Int J Oncol. 2008;32(2):405–11.
79. Cui Q, Tashiro S, Onodera S, Ikejima T. Augmentation of oridonin-induced apoptosis observed with reduced autophagy. J Pharmacol Sci. 2006;101(3):230–9.
80. Cui Q, Tashiro S, Onodera S, Ikejima T. Mechanism of downregulation of apoptosis by autophagy induced by oridonin in HeLa cells. Yao xue xue bao = Acta Pharm Sin. 2007;42(1):35–9.
81. Dai W, Zhang D, Duan C, Jia L, Wang Y, Feng F, Zhang Q. Preparation and characteristics of oridonin-loaded nanostructured lipid carriers as a controlled-release delivery system. J Microencapsul. 2010;27(3):234–41.
82. Huang J, Wu L, Tashiro S, Onodera S, Ikejima T. Bcl-2 up-regulation and P-p53 down-regulation account for the low sensitivity of murine L929 fibrosarcoma cells to oridonin-induced apoptosis. Biol Pharm Bull. 2005;28(11):2068–74.
83. Kang N, Zhang JH, Qiu F, Tashiro S, Onodera S, Ikejima T. Inhibition of EGFR signaling augments oridonin-induced apoptosis in human laryngeal cancer cells via enhancing oxidative stress coincident with activation of both the intrinsic and extrinsic apoptotic pathways. Cancer Lett. 2010;294(2):147–58.
84. Kwan HY, Yang Z, Fong WF, Hu YM, Yu ZL, Hsiao WL. The anticancer effect of oridonin is mediated by fatty acid synthase suppression in human colorectal cancer cells. J Gastroenterol. 2013;48(2):182–92.
85. Li D, Wu LJ, Tashiro S, Onodera S, Ikejima T. Oridonin inhibited the tyrosine kinase activity and induced apoptosis in human epidermoid carcinoma A431 cells. Biol Pharm Bull. 2007;30(2):254–60.
86. Li RF, Wang QD. Regulation of telomerase activity and cell cycle of K562 cells by oridonin. Yao xue xue bao = Acta Pharm Sin. 2004;39(11):865–8.
87. Liu JJ, Wu XY, Lul HL, Pan XL, Peng J, Huang RW. Anti-proliferation effect of oridonin on HL-60 cells and its mechanism. Chin Med Sci J = Chung-kuo i hsueh k’o hsueh tsa chih/Chin Acad Med Sci. 2004;19(2):134–137.
88. Liu JJ, Wu XY, Peng J, Pan XL, Lu HL. Antiproliferation effects of oridonin on HL-60 cells. Ann Hematol. 2004;83(11):691–5.
89. Bertelli AA, Ferrara F, Diana G, Fulgenzi A, Corsi M, Ponti W, Ferrero ME, Bertelli A. Resveratrol, a natural stilbene in grapes and wine, enhances intraphagocytosis in human promonocytes: a co-factor in antiinflammatory and anticancer chemopreventive activity. Int J Tissue React. 1999;21(4):93–104.
90. Sun KW, Ma YY, Guan TP, Xia YJ, Shao CM, Chen LG, Ren YJ, Yao HB, Yang Q, He XJ. Oridonin induces apoptosis in gastric cancer through Apaf-1, cytochrome c and caspase-3 signaling pathway. World J Gastroenterol. 2012;18(48):7166–74.
91. Yi S, Chen Y, Wen L, Yang L, Cui G. Downregulation of nucleoporin 88 and 214 induced by oridonin may protect OCIM2 acute erythroleukemia cells from apoptosis through regulation of nucleocytoplasmic transport of NF-kappaB. Int J Mol Med. 2012;30(4):877–83.
92. Zhang Y, Wu Y, Tashiro S, Onodera S, Ikejima T. Involvement of PKC signal pathways in oridonin-induced autophagy in HeLa cells: a protective mechanism against apoptosis. Biochem Biophys Res Commun. 2009;378(2):273–8.
93. Zhou L, Sun L, Wu H, Zhang L, Chen M, Liu J, Zhong R. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF). Eur J Pharmacol. 2013;715(1–3):230–7.
94. Bai N, He K, Zhou Z, Tsai ML, Zhang L, Quan Z, Shao X, Pan MH, Ho CT. Ent-kaurane diterpenoids from Rabdosia rubescens and their cytotoxic effects on human cancer cell lines. Planta Med. 2010;76(2):140–5.
95. Bai SP, Wei QY, Jin XL, Wu QX, Yang L. Two novel ent-kauranoid diterpenoids from Isodonjaponica leaves. Planta Med. 2005;71(8):764–9.
96. He XJ, Wang HJ, Xia YJ, Ye ZY, Tao HQ. Empirical study of oridonin-induced gastric cancer cells MKN45 apoptosis. Zhonghua wei chang wai ke za zhi = Chin J Gastrointest Surg. 2009;12(6):607–10.
97. Kang N, Zhang JH, Qiu F, Chen S, Tashiro S, Onodera S, Ikejima T. Induction of G(2)/M phase arrest and apoptosis by oridonin in human laryngeal carcinoma cells. J Nat Prod. 2010;73(6):1058–63.
98. Ren KK, Wang HZ, Xie LP, Chen DW, Liu X, Sun J, Nie YC, Zhang RQ. The effects of oridonin on cell growth, cell cycle, cell migration and differentiation in melanoma cells. J Ethnopharmacol. 2006;103(2):176–80.
99. Gao YH, Wan ZX, Lai XW, Zhu Y, Li GY, Wu SH. Chemical constituents of Rabdosia nervosa (Hemsl) C.Y. Wu et H. W. Li. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China J Chin Mater Med. 1994;19(5):295–296, 320.
100. Satooka H, Isobe T, Nitoda T, Kubo I. Melanogenesis inhibitors from Rabdosia japonica. Phytomedicine. 2012;19(11):1016–23.
101. Han QB, Li RT, Li ML, Mou YK, Tian QE, Li SW, Sun HD. Ent-kauranoids from Isodon rubescens var. taihangensis. J Asian Nat Prod Res. 2005;7(1):31–6.
102. He F, Bai Y, Wang J, Wei J, Yu C, Li S, Yang W, Han C. Isolation and purification of oridonin from the whole plant of Isodon rubescens by high-speed counter-current chromatography. Molecules. 2011;16(9):7949–57.
103. Zhao AH, Xiang W, Na Z, Wang ZY, Lin ZW, Sun HD. Cytotoxic ent-kauranoids from Isodon leucophyllus. J Asian Nat Prod Res. 2004;6(2):145–50.
104. Que S, Zhao Y, Zhou Y, Zhang Q. Two en-kaurene diterpenoids from Tibetan medicine Caryopteris toroetii. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China J Chin Mater Med. 2009;34(12):1523–6.
105. Bao R, Shu Y, Wu X, Weng H, Ding Q, Cao Y, Li M, Mu J, Wu W, Ding Q, et al. Oridonin induces apoptosis and cell cycle arrest of gallbladder cancer cells via the mitochondrial pathway. BMC Cancer. 2014;14:217.
106. Chen JH, Wang SB, Li EM, Chen LM, Yuan SJ, Wang RL, Shen ZY. Inhibitory effect of Oridonin injection on heterotransplanted gastric adenocarcinoma in nude mice and its mechanism. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2008;30(2):89–92.
107. Bohanon FJ, Wang X, Ding C, Ding Y, Radhakrishnan GL, Rastellini C, Zhou J, Radhakrishnan RS. Oridonin inhibits hepatic stellate cell proliferation and fibrogenesis. J Surg Res. 2014;190(1):55–63.
108. Wang S, Zhang Y, Saas P, Wang H, Xu Y, Chen K, Zhong J, Yuan Y, Wang Y, Sun Y. Oridonin’s therapeutic effect: suppressing Th1/Th17 simultaneously in a mouse model of Crohn’s disease. J Gastroenterol Hepatol. 2015;30(3):504–12. doi:10.1111/jgh.12710.
109. Zhou X, Zhang X, Ye Y, Zhang T, Wang H, Ma Z, Wu B. Nanostructured lipid carriers used for oral delivery of oridonin: an effect of ligand modification on absorption. Int J Pharm. 2015;479(2):391–8. doi:10.1016/j.ijpharm.2014.12.068(Epub 2014 Dec 30).
110. Gu Z, Wang X, Qi R, Wei L, Huo Y, Ma Y, Shi L, Chang Y, Li G, Zhou L. Oridonin induces apoptosis in uveal melanoma cells by upregulation of Bim and downregulation of fatty acid synthase. Biochem Biophys Res Commun. 2015;457(2):187–93. doi:10.1016/j.bbrc.2014.12.086(Epub 2014 Dec 27).
111. Xu B, Shen W, Liu X, Zhang T, Ren J, Fan Y, Xu J. Oridonin inhibits BxPC-3 cell growth through cell apoptosis. Acta Biochim Biophys Sin (Shanghai). 2015;47(3):164–73. doi:10.1093/abbs/gmu134(Epub 2015 Feb 3).